{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T08:20:24Z","timestamp":1781598024280,"version":"3.54.5"},"reference-count":107,"publisher":"Bentham Science Publishers Ltd.","issue":"6","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CNSNDDT"],"published-print":{"date-parts":[[2019,8,30]]},"abstract":"<jats:sec><jats:title>:<\/jats:title><jats:p>The development of chalcone-based compounds for CNS disorders has been explored by many research groups. Chalcones are being considered as a potent organic scaffold with widespread applications in the field of drug discovery and medicinal chemistry. The planar or semi-planar geometry of chalcones with various functionalities impinged on the terminal aromatic systems renders the molecule its bio-activity including anti-cancer, anti-malarial, anti-microbial, anti-fungal, antileishmanial, anti-viral, anti-diabetic, anti-hypertensive properties, etc. Moreover, cutting-edge research has been executed in the domain of Central Nervous System (CNS) based scheme, further, their identification and classifications also remain of high interest in the field of medicinal chemistry but the specific reviews are limited. Hence, the present review highlights the significance of chalcones toward their CNS activities (up to 2019), which include anti-depressant activity, anxiolytic activity, activity with GABA receptors, acetylcholinesterase (AChE) and butyryl cholinesterase (BChE) inhibitions, activity as adenosine receptor antagonists anti-Alzheimer\u2019s agents, \u03b2-amyloid plaques imaging agents, monoamine oxidase inhibition. To our knowledge, this is the first review exclusively for CNS activity profile of chalcones.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1871527318666190610111246","type":"journal-article","created":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T09:34:00Z","timestamp":1560332040000},"page":"432-445","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Perspective Design of Chalcones for the Management of CNS Disorders: A Mini-Review"],"prefix":"10.2174","volume":"18","author":[{"given":"Bijo","family":"Mathew","sequence":"first","affiliation":[{"name":"Division of Drug Design and Medicinal Chemistry Research Lab, Department of Pharmaceutical Chemistry, Ahalia School of Pharmacy, Palakkad 678557, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Della Grace Thomas","family":"Parambi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Jouf University, Sakaka, Al Jouf, 2014, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishnu Sankar","family":"Sivasankarapillai","sequence":"additional","affiliation":[{"name":"Department of Chemistry, NSS Hindu College, Changanacherry, Kerala, 686103, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Sahab","family":"Uddin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Southeast University, Dhaka, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerad","family":"Suresh","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, College of Pharmacy, Madras Medical College, Chennai 600004, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Githa Elizabeth","family":"Mathew","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Grace College of Pharmacy, Palakkad 678004, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monu","family":"Joy","sequence":"additional","affiliation":[{"name":"School of Pure & Applied Physics, M.G. University, Kottayam 686560, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Marathakam","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, National College of Pharmacy, Calicut 673602, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheeba Varghese","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL 33612, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.molliq.2017.07.091","volume":"242","author":"Chaves O.A.","year":"2017","unstructured":"Chaves O.A.; Mathew B.; Sobrinho D.C.; Spectroscopic, zeta potential and molecular docking analysis on the interaction between human serum albumin and halogenated thienyl chalcones. J Mol Liq 2017,242,1016-1026","journal-title":"J Mol Liq"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.2174\/0929867306666220401182509","volume":"6","author":"Dimmock J.R.","year":"1999","unstructured":"Dimmock J.R.; Elias D.W.; Beazely M.A.; Kandepu N.M.; Bioactivities of chalcones. Curr Med Chem 1999,6(12),1125-1149","journal-title":"Curr Med Chem"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.bionut.2014.04.003","volume":"4","author":"Mathew B.","year":"2014","unstructured":"Mathew B.; Suresh J.; Anbazhagan S.; Paulraj J.; Krishnan G.K.; Heteroaryl chalcones: Mini review about their therapeutic voyage. BioMed Prev Nut 2014,4,451-458","journal-title":"BioMed Prev Nut"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2174\/1568009614666140122160515","volume":"14","author":"Jandial D.D.","year":"2014","unstructured":"Jandial D.D.; Blair C.A.; Zhang S.; Krill L.S.; Zhang Y.B.; Zi X.; Molecular targeted approaches to cancer therapy and prevention using chalcones. Curr Cancer Drug Targets 2014,14(2),181-200","journal-title":"Curr Cancer Drug Targets"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.molstruc.2017.07.009","volume":"1147","author":"Mathew B.","year":"2017","unstructured":"Mathew B.; Adeniyi A.A.; Joy M.; Anti-oxidant behaviour of functionalized chalcone-a combined quantum chemical and crystallographic structural investigation. J Mol Struct 2017,1147,682-696","journal-title":"J Mol Struct"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1021\/jm300588j","volume":"56","author":"Tadigoppula N.","year":"2013","unstructured":"Tadigoppula N.; Korthikunta V.; Gupta S.; Synthesis and insight into the structure-activity relationships of chalcones as antimalarial agents. J Med Chem 2013,56(1),31-45","journal-title":"J Med Chem"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bioorg.2014.03.006","volume":"54","author":"Abdullah M.I.","year":"2014","unstructured":"Abdullah M.I.; Mahmood A.; Madni M.; Masood S.; Kashif M.; Synthesis, characterization, theoretical, anti-bacterial and molecular docking studies of quinoline based chalcones as a DNA gyrase inhibitor. Bioorg Chem 2014,54,31-37","journal-title":"Bioorg Chem"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1016\/j.ejmech.2007.12.027","volume":"43","author":"Lahtchev K.L.","year":"2008","unstructured":"Lahtchev K.L.; Batovska D.I.; Parushev S.P.; Ubiyvovk V.M.; Sibirny A.A.; Antifungal activity of chalcones: A mechanistic study using various yeast strains. Eur J Med Chem 2008,43(10),2220-2228","journal-title":"Eur J Med Chem"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/jac\/43.6.793","volume":"43","author":"Zhai L.","year":"1999","unstructured":"Zhai L.; Chen M.; Blom J.; Theander T.G.; Christensen S.B.; Kharazmi A.; The antileishmanial activity of novel oxygenated chalcones and their mechanism of action. J Antimicrob Chemother 1999,43(6),793-803","journal-title":"J Antimicrob Chemother"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1007\/s00044-011-9912-x","volume":"21","author":"Rizvi S.U.F.","year":"2012","unstructured":"Rizvi S.U.F.; Siddiqui H.L.; Johns M.; Detorio M.; Schinazi R.F.; Anti-HIV-1 and cytotoxicity studies of piperidyl-thienyl chalcones and their 2-pyrazoline derivatives. Med Chem Res 2012,21,3741-3749","journal-title":"Med Chem Res"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.bmc.2003.12.026","volume":"12","author":"Satyanarayana M.","year":"2004","unstructured":"Satyanarayana M.; Tiwari P.; Tripathi B.K.; Srivastava A.K.; Pratap R.; Synthesis and antihyperglycemic activity of chalcone based aryloxypropanolamines. Bioorg Med Chem 2004,12(5),883-889","journal-title":"Bioorg Med Chem"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bmcl.2007.10.114","volume":"18","author":"Yarishkin O.V.","year":"2008","unstructured":"Yarishkin O.V.; Ryu H.W.; Park J.Y.; Yang M.S.; Hong S.G.; Park K.H.; Sulfonate chalcone as new class voltage-dependent K+ channel blocker. Bioorg Med Chem Lett 2008,18(1),137-140","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejmech.2006.09.019","volume":"42","author":"Nowakowska Z.","year":"2007","unstructured":"Nowakowska Z.; A review of anti-infective and anti-inflammatory chalcones. Eur J Med Chem 2007,42(2),125-137","journal-title":"Eur J Med Chem"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/157488410790410579","volume":"5","author":"Batovska D.I.","year":"2010","unstructured":"Batovska D.I.; Todorova I.T.; Trends in utilization of the pharmacological potential of chalcones. Curr Clin Pharmacol 2010,5(1),1-29","journal-title":"Curr Clin Pharmacol"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2174\/092986712803414132","volume":"19","author":"Sahu N.K.","year":"2012","unstructured":"Sahu N.K.; Balbhadra S.S.; Choudhary J.; Kohli D.V.; Exploring pharmacological significance of chalcone scaffold: A review. Curr Med Chem 2012,19(2),209-225","journal-title":"Curr Med Chem"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2174\/138955713804484767","volume":"13","author":"Bukhari S.N.A.","year":"2013","unstructured":"Bukhari S.N.A.; Jantan I.; Jasamai M.; Anti-inflammatory trends of 1, 3-diphenyl-2-propen-1-one derivatives. Mini Rev Med Chem 2013,13(1),87-94","journal-title":"Mini Rev Med Chem"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.ejmech.2014.08.033","volume":"85","author":"Singh P.","year":"2014","unstructured":"Singh P.; Anand A.; Kumar V.; Recent developments in biological activities of chalcones: A mini review. Eur J Med Chem 2014,85,758-777","journal-title":"Eur J Med Chem"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ejmech.2015.06.052","volume":"101","author":"Mahapatra D.K.","year":"2015","unstructured":"Mahapatra D.K.; Bharti S.K.; Asati V.; Chalcone scaffolds as anti-infective agents: Structural and molecular target perspectives. Eur J Med Chem 2015,101,496-524","journal-title":"Eur J Med Chem"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2174\/1574892809666140819153902","volume":"10","author":"Karthikeyan C.","year":"2015","unstructured":"Karthikeyan C.; Moorthy N.S.H.N.; Ramasamy S.; Advances in chalcones with anticancer activities. Recent Pat Anti-Cans Drug Discov 2015,10(1),97-115","journal-title":"Recent Pat Anti-Cans Drug Discov"},{"key":"ref=20","first-page":"200","volume":"16","author":"Rahul S.","year":"2016","unstructured":"Rahul S.; Rakesh K.; Rishi K.; A review on mechanisms of antitumor activity of chalcones. Anticancer Agents Med Chem 2016,16,200-211","journal-title":"Anticancer Agents Med Chem"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ejmech.2015.01.051","volume":"92","author":"Mahapatra D.K.","year":"2015","unstructured":"Mahapatra D.K.; Asati V.; Bharti S.K.; Chalcones and their therapeutic targets for the management of diabetes: Structural and pharmacological perspectives. Eur J Med Chem 2015,92,839-865","journal-title":"Eur J Med Chem"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.lfs.2016.02.048","volume":"148","author":"Mahapatra D.K.","year":"2016","unstructured":"Mahapatra D.K.; Bharti S.K.; Therapeutic potential of chalcones as cardiovascular agents. Life Sci 2016,148,154-172","journal-title":"Life Sci"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1002\/cber.188101402192","volume":"14","author":"Claisen L.","year":"1881","unstructured":"Claisen L.; Clapar\u00e9de A.; Condensationen von Ketonen mit Aldehyden. Chem Ber 1881,14,2460-2468","journal-title":"Chem Ber"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1002\/cber.188101401306","volume":"14","author":"Schmidt J.G.","year":"1881","unstructured":"Schmidt J.G.; Ueber die Einwirkung von Aceton auf Furfurol und auf Bittermandel\u00f6l bei Gegenwart von Alkalilauge. Chem Ber 1881,14,1459-1461","journal-title":"Chem Ber"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1246\/bcsj.54.1195","volume":"54","author":"Kazuo I.","year":"1981","unstructured":"Kazuo I.; Ken-ichi W.; Catalysis of metal (II) acetate 2-2\u02b9bipyridine complexes in the aldol condensation. Bull Chem Soc Jpn 1981,54,1195-1198","journal-title":"Bull Chem Soc Jpn"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1002\/hlca.200490276","volume":"87","author":"Xu L.W.","year":"2004","unstructured":"Xu L.W.; Li L.; Xia C.G.; Zhao P.Q.; Efficient coupling reactions of arylalkynes and aldehydes leading to the synthesis of enones. Helv Chim Acta 2004,87,3080-3084","journal-title":"Helv Chim Acta"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"5359","DOI":"10.1016\/S0040-4039(03)01140-7","volume":"44","author":"Eddarir S.","year":"2003","unstructured":"Eddarir S.; Cotelle N.; Bakkour Y.; Rolando C.; An efficient synthesis of chalcones based on the Suzuki reaction. Tetrahedron Lett 2003,44,5359-5363","journal-title":"Tetrahedron Lett"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"14596","DOI":"10.1021\/ja1059922","volume":"132","author":"Wu X.F.","year":"2010","unstructured":"Wu X.F.; Neumann H.; Spannenberg A.; Schulz T.; Jiao H.; Beller M.; Development of a general palladium-catalyzed carbonylative Heck reaction of aryl halides. J Am Chem Soc 2010,132(41),14596-14602","journal-title":"J Am Chem Soc"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2174\/1570193X11310010006","volume":"10","author":"Bhukari S.N.A.","year":"2013","unstructured":"Bhukari S.N.A.; Jasamai M.; Jantan I.; Ahmad W.; Review of methods and various catalysts used for chalcone synthesis. Mini Rev Org Chem 2013,10,73-83","journal-title":"Mini Rev Org Chem"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1039\/b409808k","volume":"130","author":"Fringuelli F.","year":"2004","unstructured":"Fringuelli F.; Pizzo F.; Vittoriani C.; Vaccaro L.; Polystyryl-supported TBD as an efficient and reusable catalyst under solvent-free conditions. Chem Commun (Camb) 2004,130(23),2756-2757","journal-title":"Chem Commun (Camb)"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1016\/j.tetlet.2011.05.118","volume":"52","author":"Siddiqui Z.N.","year":"2011","unstructured":"Siddiqui Z.N.; Musthafa T.N.M.; An efficient and novel synthesis of chromonyl chalcones using recyclable Zn(l-proline)2 catalyst in water. Tetrahedron Lett 2011,52,4008-4013","journal-title":"Tetrahedron Lett"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/00397919708005039","volume":"27","author":"Zeng M.","year":"1997","unstructured":"Zeng M.; Wang L.; Shao J.; Zhong Q.; A facile synthesis of \u03b1, \u03b1\u2032-bis(substituted benzylidene)cycloalkanones catalyzed by bis(p-ethoxyphenyl)telluroxide(bmpto) under microwave irradiation. Synth Commun 1997,27,351-354","journal-title":"Synth Commun"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1752-153X-5-8","volume":"5","author":"Kakati D.","year":"2011","unstructured":"Kakati D.; Sarma J.C.; Microwave assisted solvent free synthesis of 1,3-diphenylpropenones. Chem Cent J 2011,5,8","journal-title":"Chem Cent J"},{"key":"ref=34","author":"Schramm O.G.","year":"2006","unstructured":"Schramm O.G.; Multi-component Heterocycle Syntheses Based Upon Sonogashira Coupling Isomerization. Thesis Heidelberg University 2006","journal-title":"Thesis Heidelberg University"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2174\/1871524915666151002124443","volume":"16","author":"Mathew B.","year":"2016","unstructured":"Mathew B.; Haridas A.; Suresh J.; Mathew G.E.; U\u00e7ar G.; Jayaprakash V.; Monoamine oxidase inhibitory actions of chalcones. A mini review. Cent Nerv Syst Agents Med Chem 2016,16(2),120-136","journal-title":"Cent Nerv Syst Agents Med Chem"},{"key":"ref=36","first-page":"437","volume":"13","author":"Mathew B.","year":"2014","unstructured":"Mathew B.; Suresh J.; Anbazhagan S.; Synthesis, preclinical evaluation and antidepressant activity of 5-substituted phenyl-3-(thiophen-2-yl)-4, 5-dihydro-1H-pyrazole-1-carbothioamides. EXCLI J 2014,13,437-445","journal-title":"EXCLI J"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1016\/j.jscs.2012.09.015","volume":"20","author":"Mathew B.","year":"2016","unstructured":"Mathew B.; Suresh J.; Anbazhagan S.; Development of novel (1-H) benzimidazole bearing pyrimidine-trione based MAO-A inhibitors: Synthesis, docking studies and antidepressant activity. J Saudi Chem Soc 2016,20,S132-S139","journal-title":"J Saudi Chem Soc"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.pnpbp.2007.12.021","volume":"32","author":"Wang W.","year":"2008","unstructured":"Wang W.; Hu X.; Zhao Z.; Antidepressant-like effects of liquiritin and isoliquiritin from Glycyrrhiza uralensis in the forced swimming test and tail suspension test in mice. Prog Neuropsychopharmacol Biol Psychiatry 2008,32(5),1179-1184","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1007\/s00044-011-9640-2","volume":"21","author":"Sui X.","year":"2012","unstructured":"Sui X.; Zhao D.H.; Qu Y.L.; Zhang R.P.; Guan L.P.; Synthesis and studies on antidepressant activity of 2\u00b4, 4\u00b4, 6\u00b4-trihydroxychalcone derivatives. Med Chem Res 2012,21,1290-1296","journal-title":"Med Chem Res"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1007\/s00044-013-0517-4","volume":"22","author":"Guan L.P.","year":"2013","unstructured":"Guan L.P.; Zhao D.H.; Chang Y.; Sun Y.; Ding X.L.; Jiang J.D.; Design, synthesis and antidepressant activity evaluation of 2-hydroxy-4-6- diisoprenylchalcone derivatives. Med Chem Res 2013,22,5218-5226","journal-title":"Med Chem Res"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2174\/157018013804142375","volume":"10","author":"Afzal O.","year":"2013","unstructured":"Afzal O.; Bawas S.; Kumar S.; Kumar R.; Hassan M.Q.; Design, synthesis and evaluation of novel 2-piperidinyl quinoline chalcones\/ amines as potential antidepressant agents. Lett Drug Des Discov 2013,10,75-85","journal-title":"Lett Drug Des Discov"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1055\/s-0032-1333229","volume":"63","author":"Guan L.P.","year":"2013","unstructured":"Guan L.P.; Zhao D.H.; Chang Y.; Wen Z.S.; Tang L.M.; Huang F.F.; Synthesis of 2,4-dihydroxychalcone derivatives as potential antidepressant effect. Drug Res (Stuttg) 2013,63(1),46-51","journal-title":"Drug Res (Stuttg)"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1472-8206.2008.00639.x","volume":"22","author":"Jamal H.","year":"2008","unstructured":"Jamal H.; Ansari W.H.; Rizvi S.J.; Evaluation of chalcones--a flavonoid subclass for their anxiolytic effects in rats using elevated plus maze and open field behaviour tests. Fundam Clin Pharmacol 2008,22(6),673-681","journal-title":"Fundam Clin Pharmacol"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.chroma.2004.05.049","volume":"1042","author":"Cao Y.","year":"2004","unstructured":"Cao Y.; Wang Y.; Ji C.; Ye J.; Determination of liquiritigenin and isoliquiritigenin in Glycyrrhiza uralensis and its medicinal preparations by capillary electrophoresis with electrochemical detection. J Chromatogr A 2004,1042(1-2),203-209","journal-title":"J Chromatogr A"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejphar.2008.03.054","volume":"587","author":"Jang E.Y.","year":"2008","unstructured":"Jang E.Y.; Choe E.S.; Hwang M.; Isoliquiritigenin suppresses cocaine-induced extracellular dopamine release in rat brain through GABA(B) receptor. Eur J Pharmacol 2008,587(1-3),124-128","journal-title":"Eur J Pharmacol"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.bbrc.2011.09.026","volume":"413","author":"Cho S.","year":"2011","unstructured":"Cho S.; Kim S.; Jin Z.; Isoliquiritigenin, a chalcone compound, is a positive allosteric modulator of GABAA receptors and shows hypnotic effects. Biochem Biophys Res Commun 2011,413(4),637-642","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.2174\/092986710791111206","volume":"17","author":"Tumiatti V.","year":"2010","unstructured":"Tumiatti V.; Minarini A.; Bolognesi M.L.; Milelli A.; Rosini M.; Melchiorre C.; Tacrine derivatives and Alzheimer\u2019s disease. Curr Med Chem 2010,17(17),1825-1838","journal-title":"Curr Med Chem"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.phrs.2003.11.017","volume":"50","author":"Giacobini E.","year":"2004","unstructured":"Giacobini E.; Cholinesterase inhibitors: New roles and therapeutic alternatives. Pharmacol Res 2004,50(4),433-440","journal-title":"Pharmacol Res"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"7615","DOI":"10.1021\/jm400990p","volume":"56","author":"Andersson C.D.","year":"2013","unstructured":"Andersson C.D.; Forsgren N.; Akfur C.; Divergent structure-activity relationships of structurally similar acetylcholinesterase inhibitors. J Med Chem 2013,56(19),7615-7624","journal-title":"J Med Chem"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/14756360400015231","volume":"20","author":"Hasan A.","year":"2005","unstructured":"Hasan A.; Khan K.M.; Sher M.; Synthesis and inhibitory potential towards acetylcholinesterase, butyrylcholinesterase and lipoxygenase of some variably substituted chalcones. J Enzyme Inhib Med Chem 2005,20(1),41-47","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=51","first-page":"40","volume":"1","author":"Saranya A.V.","year":"2012","unstructured":"Saranya A.V.; Rav S.; In vitro acetylcholinesterase inhibition activity of chalcones with phenothiazine moiety. Res J Recent Sci 2012,1,40-43","journal-title":"Res J Recent Sci"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3390\/molecules18010140","volume":"18","author":"Kang J.E.","year":"2012","unstructured":"Kang J.E.; Cho J.K.; Curtis-Long M.J.; Inhibitory evaluation of sulfonamide chalcones on \u03b2-Secretase and acylcholinesterase. Molecules 2012,18(1),140-153","journal-title":"Molecules"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"6124","DOI":"10.1016\/j.bmc.2014.08.033","volume":"22","author":"Liu H.R.","year":"2014","unstructured":"Liu H.R.; Liu X.J.; Fan H.Q.; Tang J.J.; Gao X.H.; Liu W.K.; Design, synthesis and pharmacological evaluation of chalcone derivatives as acetylcholinesterase inhibitors. Bioorg Med Chem 2014,22(21),6124-6133","journal-title":"Bioorg Med Chem"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/cbdd.12514","volume":"86","author":"Liu H.R.","year":"2015","unstructured":"Liu H.R.; Zhou C.; Fan H.Q.; Novel potent and selective acetylcholinesterase inhibitors as potential drugs for the treatment of Alzheimer\u2019s disease: Synthesis, pharmacological evaluation, and molecular modeling of amino alkyl substituted fluoro-chalcones derivatives. Chem Biol Drug Des 2015,86(4),517-522","journal-title":"Chem Biol Drug Des"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"580","DOI":"10.3109\/14756366.2015.1050009","volume":"31","author":"Liu H.","year":"2016","unstructured":"Liu H.; Fan H.; Gao X.; Design, synthesis and preliminary structure-activity relationship investigation of nitrogen-containing chalcone derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors: A further study based on Flavokawain B Mannich base derivatives. J Enzyme Inhib Med Chem 2016,31(4),580-589","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1152\/physrev.2001.81.2.741","volume":"81","author":"Selkoe D.J.","year":"2001","unstructured":"Selkoe D.J.; Alzheimer\u2019s disease: Genes, proteins, and therapy. Physiol Rev 2001,81(2),741-766","journal-title":"Physiol Rev"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1016\/j.bmcl.2013.02.103","volume":"23","author":"Bag S.","year":"2013","unstructured":"Bag S.; Ghosh S.; Tulsan R.; Design, synthesis and biological activity of multifunctional \u03b1,\u03b2-unsaturated carbonyl scaffolds for Alzheimer\u2019s disease. Bioorg Med Chem Lett 2013,23(9),2614-2618","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1002\/cmdc.201402291","volume":"9","author":"Sashidhara K.V.","year":"2014","unstructured":"Sashidhara K.V.; Modukuri R.K.; Jadiya P.; Benzofuran-chalcone hybrids as potential multifunctional agents against Alzheimer\u2019s disease: Synthesis and in vivo studies with transgenic Caenorhabditis elegans. ChemMedChem 2014,9(12),2671-2684","journal-title":"ChemMedChem"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"Hardy J.A.","year":"1992","unstructured":"Hardy J.A.; Higgins G.A.; Alzheimer\u2019s disease: The amyloid cascade hypothesis. Science 1992,256(5054),184-185","journal-title":"Science"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.2174\/1381612043384772","volume":"10","author":"Mathis C.A.","year":"2004","unstructured":"Mathis C.A.; Wang Y.; Klunk W.E.; Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain. Curr Pharm Des 2004,10(13),1469-1492","journal-title":"Curr Pharm Des"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"12084","DOI":"10.1038\/srep12084","volume":"5","author":"Yang Y.","year":"2015","unstructured":"Yang Y.; Zhang X.; Cui M.; Preliminary characterization and in vivo studies of structurally identical 18F- and 125I-labeled benzyloxybenzenes for pet\/spectimaging of \u03b2-amyloid plaques. Sci Rep 2015,5,12084","journal-title":"Sci Rep"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00259-011-2021-8","volume":"39","author":"Camus V.","year":"2012","unstructured":"Camus V.; Payoux P.; Barr\u00e9 L.; Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl Med Mol Imaging 2012,39(4),621-631","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"6388","DOI":"10.1016\/j.bmc.2007.06.055","volume":"15","author":"Ono M.","year":"2007","unstructured":"Ono M.; Hori M.; Haratake M.; Tomiyama T.; Mori H.; Nakayama M.; Structure-activity relationship of chalcones and related derivatives as ligands for detecting of \u03b2-amyloid plaques in the brain. Bioorg Med Chem 2007,15(19),6388-6396","journal-title":"Bioorg Med Chem"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"6802","DOI":"10.1016\/j.bmc.2007.07.052","volume":"15","author":"Ono M.","year":"2007","unstructured":"Ono M.; Haratake M.; Mori H.; Nakayama M.; Novel chalcones as probes for in vivo imaging of \u03b2-amyloid plaques in Alzheimer\u2019s brains. Bioorg Med Chem 2007,15(21),6802-6809","journal-title":"Bioorg Med Chem"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1021\/cn100042d","volume":"1","author":"Ono M.","year":"2010","unstructured":"Ono M.; Ikeoka R.; Watanabe H.; Synthesis and evaluation of novel chalcone derivatives with (99m)Tc\/Re complexes as potential probes for detection of \u03b2-amyloid plaques. ACS Chem Neurosci 2010,1(9),598-607","journal-title":"ACS Chem Neurosci"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.bmcl.2010.12.045","volume":"21","author":"Cui M.","year":"2011","unstructured":"Cui M.; Ono M.; Kimura H.; Liu B.L.; Saji H.; Synthesis and biological evaluation of indole-chalcone derivatives as \u03b2-amyloid imaging probe. Bioorg Med Chem Lett 2011,21(3),980-982","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1016\/j.bmc.2014.03.032","volume":"22","author":"Fuchigami T.","year":"2014","unstructured":"Fuchigami T.; Yamashita Y.; Haratake M.; Ono M.; Yoshida S.; Nakayama M.; Synthesis and evaluation of ethyleneoxylated and allyloxylated chalcone derivatives for imaging of amyloid \u03b2 plaques by SPECT. Bioorg Med Chem 2014,22(9),2622-2628","journal-title":"Bioorg Med Chem"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nrd1983","volume":"5","author":"Jacobson K.A.","year":"2006","unstructured":"Jacobson K.A.; Gao Z.G.; Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 2006,5(3),247-264","journal-title":"Nat Rev Drug Discov"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/jphp.12028","volume":"65","author":"Vazquez-Rodriguez S.","year":"2013","unstructured":"Vazquez-Rodriguez S.; Matos M.J.; Santana L.; Chalcone-based derivatives as new scaffolds for hA3 adenosine receptor antagonists. J Pharm Pharmacol 2013,65(5),697-703","journal-title":"J Pharm Pharmacol"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrn1883","volume":"7","author":"Youdim M.B.","year":"2006","unstructured":"Youdim M.B.; Edmondson D.; Tripton K.; The therapeutic potential of MAO inhibitors: Safety and future. Nat Rev Neurosci 2006,7,295-309","journal-title":"Nat Rev Neurosci"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2174\/1871524915666150831141705","volume":"16","author":"De Monte C.D.","year":"2016","unstructured":"De Monte C.D.; Ascenzio M.; Guglielmi P.; Mancini V.; Carradori S.; Opening new scenario for human MAO inhibitors. Cent Nerv Syst Agents Med Chem 2016,16(2),98-104","journal-title":"Cent Nerv Syst Agents Med Chem"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2174\/1573408012666160402001715","volume":"12","author":"Mathew B.","year":"2016","unstructured":"Mathew B.; Mathew G.E.; Suresh J.; Perspective design for the treatment of depression and neurological disorders. Curr Enzym Inhib 2016,12,115-122","journal-title":"Curr Enzym Inhib"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s11030-013-9490-6","volume":"18","author":"Carradori S.","year":"2014","unstructured":"Carradori S.; D\u2019Ascenzio M.; Chimenti P.; Secci D.; Bolasco A.; Selective MAO-B inhibitors: A lesson from natural products. Mol Divers 2014,18(1),219-243","journal-title":"Mol Divers"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1021\/jm801590u","volume":"52","author":"Chimenti F.","year":"2009","unstructured":"Chimenti F.; Fioravanti R.; Bolasco A.; Chalcones: A valid scaffold for monoamine oxidases inhibitors. J Med Chem 2009,52(9),2818-2824","journal-title":"J Med Chem"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1016\/j.bmcl.2013.06.050","volume":"23","author":"Robinson S.J.","year":"2013","unstructured":"Robinson S.J.; Petzer J.P.; Petzer A.; Bergh J.J.; Lourens A.C.U.; Selected furanochalcones as inhibitors of monoamine oxidase. Bioorg Med Chem Lett 2013,23(17),4985-4989","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"7890","DOI":"10.1016\/j.bmc.2013.10.004","volume":"21","author":"Jo G.","year":"2013","unstructured":"Jo G.; Ahn S.; Kim B.G.; Chromenylchalcones with inhibitory effects on monoamine oxidase B. Bioorg Med Chem 2013,21(24),7890-7897","journal-title":"Bioorg Med Chem"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1016\/j.bmcl.2014.06.015","volume":"24","author":"Evranos-Aks\u00f6z B.","year":"2014","unstructured":"Evranos-Aks\u00f6z B.; Yabano\u011flu-\u00c7ift\u00e7i S.; U\u00e7ar G.; Yelek\u00e7i K.; Ertan R.; Synthesis of some novel hydrazone and 2-pyrazoline derivatives: Monoamine oxidase inhibitory activities and docking studies. Bioorg Med Chem Lett 2014,24(15),3278-3284","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"6486","DOI":"10.1016\/j.bmc.2015.08.012","volume":"23","author":"Choi J.W.","year":"2015","unstructured":"Choi J.W.; Jang B.K.; Cho N.C.; Synthesis of a series of unsaturated ketone derivatives as selective and reversible monoamine oxidase inhibitors. Bioorg Med Chem 2015,23(19),6486-6496","journal-title":"Bioorg Med Chem"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ardp.201500212","volume":"348","author":"Evranos-Aks\u00f6z B.","year":"2015","unstructured":"Evranos-Aks\u00f6z B.; Baysal \u0130.; Yabano\u011flu-\u00c7ift\u00e7i S.; Synthesis and screening of human monoamine oxidase-A inhibitor effect of new 2-pyrazoline and hydrazone derivatives. Arch Pharm (Weinheim) 2015,348(10),743-756","journal-title":"Arch Pharm (Weinheim)"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.bioorg.2015.07.001","volume":"62","author":"Mathew B.","year":"2015","unstructured":"Mathew B.; Mathew G.E.; U\u00e7ar G.; Development of fluorinated methoxylated chalcones as selective monoamine oxidase-B inhibitors: Synthesis, biochemistry and molecular docking studies. Bioorg Chem 2015,62,22-29","journal-title":"Bioorg Chem"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2174\/1570178612666150903213416","volume":"12","author":"Mathew B.","year":"2015","unstructured":"Mathew B.; U\u00e7ar G.; Yabano\u011flu-\u00c7ift\u00e7i S.; Development of fluorinated thienylchalcones as monoamine oxidase-b inhibitors: Design, synthesis, biological evaluation and molecular docking studies. Lett Org Chem 2015,12,605-613","journal-title":"Lett Org Chem"},{"key":"ref=82","doi-asserted-by":"crossref","first-page":"580","DOI":"10.2174\/1573406410666141226131252","volume":"11","author":"Zaib S.","year":"2015","unstructured":"Zaib S.; Rizvi S.U.F.; Aslam S.; Quinolinyl-thienyl chalcones as monoamine oxidase inhibitors and their in silico modeling studies. Med Chem 2015,11(6),580-589","journal-title":"Med Chem"},{"key":"ref=83","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2174\/1573406410666141229101130","volume":"11","author":"Zaib S.","year":"2015","unstructured":"Zaib S.; Farooq Rizvi S.U.; Aslam S.; Ahmad M.; Al-Rashida M.; Iqbal J.; Monoamine oxidase inhibition and molecular modeling studies of piperidyl-thienyl and 2-pyrazoline derivatives of chalcones. Med Chem 2015,11(5),497-505","journal-title":"Med Chem"},{"key":"ref=84","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/cbdd.12458","volume":"85","author":"Morales-Camilo N.","year":"2015","unstructured":"Morales-Camilo N.; Salas C.O.; Sanhueza C.; Synthesis, biological evaluation, and molecular simulation of chalcones and aurones as selective MAO-B inhibitors. Chem Biol Drug Des 2015,85(6),685-695","journal-title":"Chem Biol Drug Des"},{"key":"ref=85","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1016\/j.bmcl.2015.09.049","volume":"25","author":"Minders C.","year":"2015","unstructured":"Minders C.; Petzer J.P.; Petzer A.; Lourens A.C.U.; Monoamine oxidase inhibitory activities of heterocyclic chalcones. Bioorg Med Chem Lett 2015,25(22),5270-5276","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=86","first-page":"1046","volume":"2-16","author":"Mathew B","unstructured":"Mathew B; Mathew GE; Ucar G; Baysal I; Suresh J; Mathew S; Potent and selective monoamine oxidase-b inhibitory activity: Fluoro vs. trifluoromethyl-4-hydroxylated chalcone derivatives Chem Biodivers ,2-16(13),1046-52","journal-title":"Chem Biodivers"},{"key":"ref=87","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/cmdc.201600497","volume":"11","author":"Mathew B.","year":"2016","unstructured":"Mathew B.; U\u00e7ar G.; Mathew G.E.; Monoamine oxidase inhibitory activity: Methyl- versus chloro-chalcone derivatives. ChemMedChem 2016,11(24),2649-2655","journal-title":"ChemMedChem"},{"key":"ref=88","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejmech.2016.02.038","volume":"114","author":"Hammuda A.","year":"2016","unstructured":"Hammuda A.; Shalaby R.; Rovida S.; Edmondson D.E.; Binda C.; Khalil A.; Design and synthesis of novel chalcones as potent selective monoamine oxidase-B inhibitors. Eur J Med Chem 2016,114,162-169","journal-title":"Eur J Med Chem"},{"key":"ref=89","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.ijbiomac.2016.05.110","volume":"91","author":"Mathew B.","year":"2016","unstructured":"Mathew B.; Haridas A.; U\u00e7ar G.; Exploration of chlorinated thienyl chalcones: A new class of monoamine oxidase-B inhibitors. Int J Biol Macromol 2016,91,680-695","journal-title":"Int J Biol Macromol"},{"key":"ref=90","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1002\/cmdc.201600122","volume":"11","author":"Mathew B.","year":"2016","unstructured":"Mathew B.; Haridas A.; U\u00e7ar G.; Synthesis, biochemistry, and computational studies of brominated thienyl chalcones: A new class of reversible MAO-B inhibitors. ChemMedChem 2016,11(11),1161-1171","journal-title":"ChemMedChem"},{"key":"ref=91","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1021\/acs.jpcb.6b09451","volume":"121","author":"Mathew B.","year":"2017","unstructured":"Mathew B.; Adeniyi A.A.; Dev S.; Pharmacophore based 3D-QSAR analysis of thienyl chalcone as new class of human MAO-B inhibitors. Investigation of combined quantum chemical and molecular dynamics approach. J Phys Chem B 2017,121(6),1186-1203","journal-title":"J Phys Chem B"},{"key":"ref=92","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/ardp.201600088","volume":"349","author":"Sasidharan R.","year":"2016","unstructured":"Sasidharan R.; Manju S.L.; U\u00e7ar G.; Baysal I.; Mathew B.; Identification of indole based chalcones: Discovery of potent, selective and reversible class of MAO-B inhibitors. Arch Pharm (Weinheim) 2016,349(8),627-637","journal-title":"Arch Pharm (Weinheim)"},{"key":"ref=93","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/slct.201802665","volume":"4","author":"Chaves O.A.","year":"2019","unstructured":"Chaves O.A.; Sasidharan R.; dos Santos de Oliveria C.H.C.; In vitro study of the interaction between HSA and indolylchalcone, a potent human MAO-B inhibitor: Spectroscopic and molecular modeling studies. ChemistrySelect 2019,4,1007-1014","journal-title":"ChemistrySelect"},{"key":"ref=94","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.ijbiomac.2017.05.162","volume":"104","author":"Mathew B","year":"2017","unstructured":"Mathew B; Mathew GE; Ucar G; Monoamine oxidase inhibitory activity of methoxy-substituted chalcones. Int J Biol Macromol 2017,104(Pt A),1321-9","journal-title":"Int J Biol Macromol"},{"key":"ref=95","doi-asserted-by":"crossref","first-page":"11113","DOI":"10.1002\/slct.201702141","volume":"2","author":"Mathew B.","year":"2017","unstructured":"Mathew B.; Ucar G.; Raphael C.; Mathew G.E.; Joy M.; Machaba K.E.; Characterization of thienylchalcones as hMAO-B inhibitors: Synthesis, biochemistry and molecular dynamics studies. ChemistrySelect 2017,2,11113-11119","journal-title":"ChemistrySelect"},{"key":"ref=96","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ijbiomac.2017.11.159","volume":"108","author":"Suresh J.","year":"2018","unstructured":"Suresh J.; Baek S.C.; Ramakrishnan S.P.; Kim H.; Mathew B.; Discovery of potent and reversible MAO-B inhibitors as furanochalcones. Int J Biol Macromol 2018,108,660-664","journal-title":"Int J Biol Macromol"},{"key":"ref=97","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.biopha.2018.06.064","volume":"106","author":"Sasidharan R.","year":"2018","unstructured":"Sasidharan R.; Baek S.C.; Sreedharannair Leelabaiamma M.; Kim H.; Mathew B.; Imidazole bearing chalcones as a new class of monoamine oxidase inhibitors. Biomed Pharmacother 2018,106,8-13","journal-title":"Biomed Pharmacother"},{"key":"ref=98","volume":"352","author":"Mathew B.","year":"2019","unstructured":"Mathew B.; Baek S.C.; Thomas Parambi D.G.; Potent and highly selective dual-targeting monoamine oxidase-B inhibitors: Fluorinated chalcones of morpholine versus imidazole. Arch Pharm (Weinheim) 2019,352(4)","journal-title":"Arch Pharm (Weinheim)"},{"key":"ref=99","doi-asserted-by":"crossref","first-page":"6614","DOI":"10.1002\/slct.201901093","volume":"4","author":"Lakshminarayan B.","year":"2019","unstructured":"Lakshminarayan B.; Baek S.C.; Kannappan N.; Ethoxylated head of chalcones as a new class of Multi-targeted MAO inhibitors. ChemistrySelect 2019,4,6614-6619","journal-title":"ChemistrySelect"},{"key":"ref=100","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1517\/13543776.2011.596529","volume":"21","author":"Katsori A.M.","year":"2011","unstructured":"Katsori A.M.; Hadjipavlou-Litina D.; Recent progress in therapeutic applications of chalcones. Expert Opin Ther Patents 2011,21(10),1575-96","journal-title":"Expert Opin Ther Patents"},{"key":"ref=101","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1517\/13543776.2014.995627","volume":"25","author":"Matos M.J.","year":"2014","unstructured":"Matos M.J.; Vazquez-Rodriguez S.; Uriarte E.; Santana L.; Potential pharmacological uses of chalcones: A patent review. Expert Opin Ther Patents 2014,25(3),351-66","journal-title":"Expert Opin Ther Patents"},{"key":"ref=102","year":"2013","unstructured":"Tissue transglutaminase inhibitors containing chalcone derivatives (1-thienyl-3-phenyl-2-propen-1-ones) and anti- Alzheimer agents containing them. Toray Industries2013"},{"key":"ref=103","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2174\/1871527317666180611090006","volume":"17","author":"Zhao H.F.","year":"2018","unstructured":"Zhao H.F.; Wang G.; Wu C.P.; A multi-targeted natural flavonoid myricetin suppresses lamellipodia and focal adhesions formation and impedes glioblastoma cell invasiveness and abnormal motility. CNS Neurol Disord Drug Targets 2018,17(7),557-567","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=104","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2174\/1871527315666161107090525","volume":"16","author":"Neganova M.E.","year":"2017","unstructured":"Neganova M.E.; Klochkov S.G.; Petrova L.N.; Securinine derivatives as potential anti-amyloid therapeutic approach. CNS Neurol Disord Drug Targets 2017,16(3),351-355","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=105","doi-asserted-by":"crossref","first-page":"92","DOI":"10.2174\/1871527317666181114141129","volume":"18","author":"Dereli F.T.G.","year":"2019","unstructured":"Dereli F.T.G.; Ilhan M.; Akkol E.K.; New drug discovery from medicinal plants and phytoconstituents for depressive disorders. CNS Neurol Disord Drug Targets 2019,18(2),92-102","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=106","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2174\/1871527317666181004155136","volume":"18","author":"Sharma S.","year":"2019","unstructured":"Sharma S.; Sarathlal K.C.; Taliyan R.; Epigenetics in neurodegenerative diseases: The role of histone deacetylases. CNS Neurol Disord Drug Targets 2019,18(1),11-18","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=107","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2174\/1871527317666180816100203","volume":"17","author":"Kumar A.","year":"2018","unstructured":"Kumar A.; Dhawan A.; Kadam A.; Shinde A.; Autophagy and mitochondria: Targets in neurodegenerative disorders. CNS Neurol Disord Drug Targets 2018,17(9),696-705","journal-title":"CNS Neurol Disord Drug Targets"}],"container-title":["CNS &amp; Neurological Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/172436","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T13:51:35Z","timestamp":1663681895000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/172436\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,30]]},"references-count":107,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,8,30]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871527318666190610111246","relation":{},"ISSN":["1871-5273"],"issn-type":[{"value":"1871-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8,30]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-03-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-09","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}